Review Article

Hepatitis B in Pregnancy

Authors: Grant Whittaker, MD, Jorge L. Herrera, MD

Abstract

In the United States each year, 24,000 infants are born to women who are infected with the hepatitis B virus (HBV) and an estimated 1000 newborns acquire the infection through vertical transmission from their mother. The approach to a pregnant patient with HBV infection includes assessing the need for therapy in the mother and evaluating possible interventions that may reduce mother-to-child transmission of HBV infection. Rates of mother-to-child transmission of HBV can be greatly reduced if the current guidelines for screening and immunization are universally followed. The use of oral antiviral therapy in highly viremic mothers to reduce mother-to-child transmission is controversial but should be considered on a case-by-case basis, realizing that the available antiviral medications to treat HBV are not approved by the Food and Drug Administration for use during pregnancy. We review the literature and present our suggested management approach to the pregnant patient with chronic HBV.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Gambarin-Gelwan M. Hepatitis B in pregnancy. Clin Liver Dis 2007;11:945-963.
 
2. Euler GL, Wooten KG, Baughman AL, et al. Hepatitis B surface antigen prevalence among pregnant women in urban areas: implications for testing, reporting and preventing perinatal transmission. Pediatrics 2003;111:1192-1197.
 
3. US Preventive Services Task Force. Screening for hepatitis B Virus infection in pregnancy: US Preventive Services Task Force Reaffirmation recommendation statement. Ann Intern Med 2009;150:869-873.
 
4. Ward JW. Time for renewed commitment to viral hepatitis prevention. Am J Public Health 2008;98:779-781.
 
5. Wong S, Chan LY, Yu V, et al. Hepatitis B carrier and perinatal outcome in singleton pregnancy. Am J Perinatol 1999;16:495-488.
 
6. Nguyen G, Garcia RT, Nguyen N, et al. Clinical course of hepatitis B virus infection during pregnancy. Aliment Pharmacol Ther 2009;29:755-764.
 
7. Connell LE, Salihu HM, Salemi JL, et al. Maternal hepatitis b and hepatitis c carrier status and perinatal outcomes. Liv Int 2011;31:1163-1170.
 
8. Lin HH, Chen PJ, Chen DS, et al. Postpartum subsidence of hepatitis B viral replication in HBeAg-positive carrier mothers. J Med Virol 1989;29:1-6.
 
9. Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50:661-662.
 
10. Fattovich G. Natural history of hepatitis B. J Hepatol 2003;39:S50-S58.
 
11. Ranger-Rogez S, Denies F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther 2004;2:133-145.
 
12. Hyams KC. Risk of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis 1995;20:992-1000.
 
13. Ornoy A, Tenenbaum A. Pregnancy outcome following infections by coxsackie, echo, measles, mumps, hepatitis, polio and encephalitis viruses. Reprod Toxicol 2006;21:446-457.
 
14. Xu DZ, Yan YP, Choi BC, et al. Risk factors and mechanism of transplacental transmission of hepatitis b virus: a case-control study. J Med Virol 2002;67:20-26.
 
15. Tran TT. Management of hepatitis B in pregnancy: weighing the options. Clev Clin J Med 2009;76:S25-S29.
 
16. Towers CV, Asrat T, Rummney P. The presence of hepatitis B surface antigen and deoxyribonucleic acid in amniotic fluid and cord blood. Am J Obstet Gynecol 2001;184:1514-1518.
 
17. Borgia G, Carleo MA, Gaeta GB, et al. Hepatitis B in pregnancy. World J Gastroenterol 2012;18:4677-4683.
 
18. Yang J, Zeng XM, Men YL, et al. Elective caesarean section versus vaginal delivery for preventing mother-to-child transmission of hepatitis B virus-a systematic review. Virol J 2008;5:100.
 
19. Chen HL, Lin LH, Hu FC, et al. Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 2012;142:773-781.
 
20. Wiseman E, Fraser MA, Holden S, et al. Perinatal transmission of hepatitis B virus: an Australian experience. Med J Aust 2009;190:489-492.
 
21. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54(RR-16):1-31.
 
22. Shahmoradi S, Yahyapour Y, Mahmodi M, et al. High prevalence of occult hepatitis B virus infection in children born to HBsAg-positive mothers despite prophylaxis with hepatitis B vaccination and HBIG. J Hepatol 2012;57:515-521.
 
23. Brown RS Jr, Verna EC, Pereira MR, et al. Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. J Hepatol 2012;57:953-959.
 
24. Buchanan C, Tran TT. Management of chronic hepatitis b in pregnancy. Clin Liver Dis 2010;14:495-504.
 
25. Pan CQ, Han GR, Jiang HX, et al. Telbivudine prevents vertical transmission from HBeAg-positive women with chronic hepatitis B. Clin Gastroenterol Hepatol 2012;10:520-526.
 
26. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011; 55:1215-1221.
 
27. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepatol 2003;10:294-297.
 
28. Xu WM, Cui YT, Wang L, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis b;a multicenter, randomized, double-blind, placebo-controlled study. J Viral Hepatol 2009;16:94-103.
 
29. Su GG, Pan KH, Fang SH, et al. Efficacy and safety of lamivudine treatment for chronic hepatitis B in pregnancy. World J Gastroenterol 2004;10:910-912.
 
30. Pan CQ, Mi LJ, Bunchorntauakul C, et al. Tenofovir disoproxil fumarate for prevention of vertical transmission of hepatitis B infection by highly viremic pregnant women: a case series. Dig Dis Sci 2012;57:2423-2429.
 
31. Shi Z, Yang Y, Ma L, et al. Lamivudine in late pregnancy to interrupt in utero transmission of hepatitis B virus: a systematic review and meta-analysis. Obstet Gynecol 2010;116:147-159.
 
32. Han L, Zhang HW, Xie JX. A meta-analysis of lamivudine for interruption of mother-to- child transmission of hepatitis B virus. World J Gastoenterol 2011;17:4321-4333.
 
33. Deng M, Zhou X, Gao S, et al. The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: systematic review and meta-analysis. Virol J 2012;9:185-198.
 
34. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother-to-child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012;10:452-459.
 
35. Shi Z, Yan Y, Wang H, et al. Breastfeeding of newborns by mothers carrying hepatitis B virus. a meta-analysis and systematic review. Arch Pediatr Adolesc Med 2011;165:837-846.